FDA Approves Lucentis Biosimilar Nufymco - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves Lucentis Biosimilar Nufymco

Ranibizumab-leyk (Nufymco) is approved for all Lucentis indications.

  • By

  • mdspire news news staff

  • January 2, 2026

  • 1 min

Share

  • 1

    The FDA approved Nufymco, a biosimilar of Lucentis, developed by Bioeq, a joint venture of Formycon AG and Polpharma Biologics Group.

  • 2

    Nufymco is indicated for treating wet macular degeneration, diabetic macular edema, diabetic retinopathy, and other eye conditions.

  • 3

    Zydus Lifesciences Limited will market Nufymco in the United States, having previously secured rights for another biosimilar.

  • 4

    Dr. Stefan Glombitza, CEO of Formycon AG, highlighted the approval as a milestone in biosimilar development.

  • 5

    The partnership aims to enhance access to affordable ranibizumab biosimilars for ophthalmic patients in the US.

Original Source(s)

FDA Approves Lucentis Biosimilar Nufymco

  • by mdspire news news staff

  • January 2, 2026

Related Content

Blindness Linked to Higher Loneliness Scores

Analysis of more than 61,000 patients found higher odds of elevated loneliness scores among those reporting blindness and those with diabetic retinopathy, but not among patients with glaucoma or age-related macular degeneration.

Oculomics: Beyond the Buzzword

Joseph J. Pizzimenti, OD, FAAO, FORS, discusses the capabilities of oculomics in retina and neuro-ophthalmology,

Expanding Imaging Capabilities

Optos’ new Silverstone platform seeks to narrow the gap between visualization and structural insight in retinal imaging

  • June 1, 2026

  • 3 min